Volterra Technologies LP Acquires 18,009 Shares of CVS Health Corporation $CVS

Volterra Technologies LP boosted its stake in shares of CVS Health Corporation (NYSE:CVS) by 271.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,644 shares of the pharmacy operator’s stock after purchasing an additional 18,009 shares during the period. Volterra Technologies LP’s holdings in CVS Health were worth $1,858,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank purchased a new position in CVS Health during the second quarter valued at approximately $1,358,698,000. Invesco Ltd. raised its position in shares of CVS Health by 15.3% during the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares during the period. Capital Research Global Investors boosted its holdings in CVS Health by 24.5% in the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in CVS Health by 70.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after buying an additional 2,188,307 shares during the period. Finally, Vanguard Group Inc. increased its stake in CVS Health by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after buying an additional 2,063,737 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Price Performance

Shares of CVS Health stock opened at $76.14 on Friday. The firm has a market cap of $96.87 billion, a PE ratio of 55.17, a PEG ratio of 0.79 and a beta of 0.49. The stock has a 50 day moving average of $78.17 and a 200 day moving average of $77.74. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. During the same period in the prior year, the firm earned $1.19 EPS. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio is currently 192.75%.

Analyst Ratings Changes

Several equities analysts have recently commented on CVS shares. Wolfe Research lowered their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Piper Sandler reissued an “overweight” rating and set a $101.00 target price (up from $99.00) on shares of CVS Health in a research note on Wednesday, December 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Finally, Truist Financial set a $100.00 price objective on shares of CVS Health in a research report on Wednesday, December 10th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.